{"analyses":[{"ciLowerLimit":"1.19","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"7.28","groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.0114","paramType":"Difference in LS Mean","paramValue":"4.24","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-2.30","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"3.57","groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.3600","paramType":"Difference in LS Mean","paramValue":"0.64","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"1.06","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"7.17","groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.0138","paramType":"Difference in LS Mean","paramValue":"4.11","statisticalMethod":"MMRM analysis; 1-sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-1.60","upperLimit":"2.63","value":"0.52"},{"groupId":"OG001","lowerLimit":"2.54","upperLimit":"6.97","value":"4.76"},{"groupId":"OG002","lowerLimit":"-0.90","upperLimit":"3.20","value":"1.15"},{"groupId":"OG003","lowerLimit":"2.40","upperLimit":"6.85","value":"4.63"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"27"}],"units":"Participants"}],"description":"FAACT-ACS is a 12-item symptom-specific subscale to measure participants' concerns about their anorexia (appetite) or cachexia (weight) for past 7 days. Each item was scored from 0 to 4, where 0= not at all, 1= a little bit, 2= somewhat, 3= quite a bit, and 4= very much. The total FAACT-ACS score ranged from 0 to 48. Higher scores are associated with a higher health-related quality of life. FAACT-ACS was analyzed using an MMRM model.","dispersionType":"90% Confidence Interval","groups":[{"description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses).","id":"OG000","title":"Part A: Placebo"},{"description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG001","title":"Part A: Ponsegromab 100 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG002","title":"Part A: Ponsegromab 200 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG003","title":"Part A: Ponsegromab 400 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Censored analysis set:all evaluable participants.For participants who discontinued study intervention/received prohibited procedure/ prohibited medication,all observations post-discontinuation/post-procedure,were censored and treated as missing data.For participants who missed dose/received incomplete dose,all observations post-missed/incomplete dose were censored and treated as missing data.''Overall Number of Participants Analyzed'' =participants evaluable for this outcome measure at Week 12.","reportingStatus":"POSTED","timeFrame":"Baseline (prior to dose on Day 1), Week 12","title":"Part A: Change From Baseline in Functional Assessment of Anorexia-Cachexia Therapy- Anorexia and Cachexia Subscale (FAACT-ACS) at Week 12","type":"SECONDARY","unitOfMeasure":"Units on a scale"}